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Abstract 
Background: Clinical diagnostic research relies upon the collection of tissue samples, and for those samples to be 
representative of the in vivo situation. Tissue collection procedures, including post-operative ischemia, can impact 
the molecular profile of the tissue at the genetic and proteomic level. Understanding the influence of factors such as 
ischemia on tissue samples is imperative in order to develop both markers of tissue quality and ultimately accurate 
diagnostic tests.
Methods: Using NanoPro1000 technology, a rapid and highly sensitive immunoassay platform, the phosphoryla-
tion status of clinically relevant cancer-related biomarkers in response to ischemia was quantified in tissue samples 
from 20 patients with primary colorectal cancer. Tumor tissue and adjacent normal tissue samples were collected and 
subjected to cold ischemia prior to nanoproteomic analysis of AKT, ERK1/2, MEK1/2, and c-MET. Ischemia-induced 
relative changes in overall phosphorylation and phosphorylation of individual isoforms were calculated and statisti-
cal significance determined. Any differences in baseline levels of phosphorylation between tumor tissue and normal 
tissue were also analyzed.
Results: Changes in overall phosphorylation of the selected proteins in response to ischemia revealed minor varia-
tions in both normal and tumor tissue; however, significant changes were identified in the phosphorylation of indi-
vidual isoforms. In normal tissue post-operative ischemia, phosphorylation was increased in two AKT isoforms, two 
ERK1/2 isoforms, and one MEK1/2 isoform and decreased in one MEK1/2 isoform and one c-MET isoform. Following 
ischemia in tumor tissue, one AKT isoform showed decreased phosphorylation and there was an overall increase in 
unphosphorylated ERK1/2, whereas an increase in the phosphorylation of two MEK1/2 isoforms was observed. There 
were no changes in c-MET phosphorylation in tumor tissue.
Conclusion: This study provides insight into the influence of post-operative ischemia on tissue sample biology, 
which may inform the future development of markers of tissue quality and assist in the development of diagnostic 
tests.
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Background
Reliable development of diagnostic tools, identification 
of therapeutic targets, and especially accurate molecular 
stratification of patients all rely on the availability and 
appropriate collection of human tissue samples [1, 2]. It 
is well known that the tissue collection procedure itself 
can have a significant impact on the analysis of data [3, 
4]; therefore, understanding and controlling exogenous 
factors is crucial to the accurate interpretation of results 
[2, 3, 5]. Furthermore, whereas scientists are familiar 
with minimizing and controlling experimental variables, 
they are often unaware of the molecular variability of tis-
sue samples. Studies have described how post-surgical 
ischemia influences the molecular composition of tis-
sues at the mRNA level [6–8], as well as at the proteome 
level [9–11]. These observations indicate that exogenous 
parameters can influence tissue samples in a way that 
may not reflect the real-life molecular profile of the tissue 
in vivo.
The effect of intra-operative ischemia on the molecular 
composition of post-surgical tissues is largely unknown. 
Intra-operative samples taken prior to vessel ligation 
may more closely represent the in vivo situation and may 
be an appropriate reference for the characterization of 
post-surgical changes due to “cold” ischemia. Available 
data, although limited, have demonstrated that protein 
expression patterns are significantly altered in tissues 
within 30  min post-resection (post-operative ischemia) 
[9, 11]. Furthermore, protein phosphorylation and gene 
expression patterns were found to be affected at the time 
blood supply to the tissue was interrupted during surgery 
(i.e., intra-operative ischemia) [12, 13]. A better under-
standing of the effects of intra- as well as post-operative 
ischemia on tissues will help distinguish the molecular 
changes that are due to ischemia from those due to dis-
ease processes. An improved description of ischemia-
induced changes in tissues may ultimately provide a 
better understanding of how clinically relevant markers 
have to be interpreted and how this will affect patient 
stratification, particularly staging, prognosis, and selec-
tion of appropriate targeted treatment [14, 15].
Oncology is a medical specialty that has seen consid-
erable progress in the development of targeted therapies. 
Monoclonal antibodies and small molecules have been 
developed that target specific receptor tyrosine kinases 
and intracellular protein kinases, and many are/have 
been developed alongside a companion diagnostic. As 
with any new drug or molecular test, the reliability of a 
companion diagnostic depends upon the tissue sample 
data used in its development.
NanoPro1000 technology enables the differential quan-
tification of protein isoforms and their phosphorylation 
status in a single measurement using very small amounts 
of protein. Protein can be detected at picogram lev-
els, allowing analysis of post-translational modification 
in samples where limited protein is available [16] (e.g., 
samples from small-needle biopsies) and making this 
a valid technology for the clinical setting. In contrast to 
the commonly used antibody-based assays (e.g., ELISA 
or western blotting), NanoPro1000 has the potential to 
characterize protein phosphorylation of multiple sites 
using just one pan-antibody. NanoPro1000 combines 
isoelectric focusing of proteins with sensitive chemilumi-
nescence detection with highly specific antibodies, pro-
viding a sensitive and quantitative approach to analyzing 
protein phosphorylation [17]. The approach is fast, with 
the ability to analyze dozens of samples with multiple 
antibodies [18].
The current study investigated changes in protein 
phosphorylation of cancer-related cell signaling mol-
ecules in response to tissue ischemia in colorectal tissue 
using the NanoPro1000 technology and the Meso Scale 
Discovery technology. The analyzed targets [members of 
the AKT and MAP-kinase pathways, as well as the recep-
tor tyrosine kinase, c-MET and EGFR (epidermal growth 
factor receptor)] have clinical relevance in the context of 
targeted therapy, and therefore the influence of ischemia 
on these molecules may have an impact on the clinical 
situation of patients.
Methods
Patients
Patients with primary colorectal cancer (CRC) and 
tumor(s) larger than 3  cm in diameter were enrolled. 
Patients gave written informed consent for the use and 
storage of biospecimen and clinical data (Additional 
file 1: Table S1). Patients with smaller tumors or who had 
received chemotherapy or radiation therapy less than 
3  weeks before surgery were excluded. The study was 
conducted at two different sites in Hamburg, Germany, 
and was approved by the competent ethics committee 
under the reference number PV3342. Therein the use of 
human biospecimens for research purpose was approved 
and the compliance with data protection regulations 
regarding the anonymization of the samples was ensured.
Tissue collection before and during surgery
After induction of anesthesia, patients underwent colo-
noscopy, during which three biopsies each were taken 
from the tumor (T) and the adjacent normal tissue (N). 
(Throughout this manuscript, this time point will be des-
ignated as 0). Following resection of the tumor and adja-
cent normal tissue, 12 tissue samples each were collected 
from the tumor and the adjacent normal tissue. These 
24 tissue samples were divided into three groups and 
exposed to a cold ischemia time of 10 min (10), 20 min 
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(20), and 45 min (45). Every tissue sample was approxi-
mately 5 × 5 × 5 mm and 120 mg. For each of the time 
points and each tissue type (normal or tumor), half of the 
samples were immediately stored in the vapor phase of 
liquid nitrogen, and half were immersion-fixed in 4 % for-
maldehyde. In this study, only frozen tissue samples were 
used. Tumor content enrichment to ≥50 % was achieved 
by either macrodissection or microdissection. Study 
workflow of sample handling and preparation is shown in 
Fig. 1.
Laser capture microdissection (LCM) of colorectal tissues
For this study, LCM was used to isolate and purify cancer 
cells from any tissue samples with an overall tumor con-
tent of <50 %. Any samples not eligible for macrodissec-
tion were subjected to LCM. A mean of 15 mm2 of LCM 
material was prepared from each sample to yield suffi-
cient protein for subsequent analyses. The prepared sam-
ples were then used for proteomic analysis (see Fig. 1).
Cell culture of control cells
The human cancer cell lines used as controls in Nano-
Pro1000 experiments were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM)/Ham’s F12 basal medium 
(HT29) or RPMI 1640 basal medium (Jurkat) containing 
10 % fetal calf serum and 2 mM l-glutamine. Cells were 
grown in standard conditions at 37 °C and 5 % CO2, and 
signal molecule phosphorylation was stimulated or inhib-
ited by compound treatment. Run controls were included 
in every run measuring patient material to ensure techni-
cal accuracy (Table 1), also see section “Run controls and 
inter-assay variation”.
Preparation of protein lysates from tissues for proteomic 
analysis
Protein lysates for NanoPro1000 analysis were pre-
pared from fresh frozen tissue blocks. From each sam-
ple, 10–15 frozen tissue slices (20 µm) were washed once 
with cold Dulbecco’s phosphate-buffered saline (DPBS) 
containing protease-inhibitor cocktails. The protein 
lysate was prepared by incubating the tissue slices with 
Tris-lysis buffer, including phosphatase and protease 
inhibitors, for 30–60 min on ice. To ensure proper mix-
ing during incubation, the tube was vortexed briefly 
every 10  min, followed by centrifugation at 13,000×g 
for 10 min at 4 °C to remove remaining cell debris. The 
supernatant was transferred to fresh tubes and stored 
at −80 °C. An aliquot was used to measure total protein 
concentration using a bicinchoninic acid (BCA) protein 
assay.
Sample collection:
normal and tumor tissue
0 min 10 min 20 min 45 min
Preparation of protein
lystates and determination of
total protein concentration
NanoProTM 1000 analysisDetermination of tumor content
0% tumor content 
Tumor
50% tumor content 
<50% tumor content 
Normal
Macrodissection (if possible)
or laser capture
microdissection
Lysate preparation 
ERK1/2, 
AKT,
MEK1/2,
c-MET
Colonoscopy (time point 0) and 10 min,
20 min and 45 min post resection
(cold ischemia)
Fig. 1 Study workflow indicating cold ischemia time points, quality control of samples, and subsequent proteomic analysis. Patient samples were 
collected at time point 0 and subjected to cold ischemia. Subsequently, the tumor content of samples was adjusted to ≥50 % and protein lysates 
were prepared for further proteomic analysis
Table 1 Cell-line run controls
Compound-treated and compound-untreated cell lines have were as positive and negative controls for protein phosphorylation in order to control run quality. 
Compound treatment of cell lines is shown
Name Origin Treatment Control Provider
Jurkat Human acute lymphocytic leukemia 200 nM PMA for 15 min Positive for AKT, ERK1/2, and MEK1/2 
phosphorylation
Indivumed GmbH
Jurkat Human acute lymphocytic leukemia 1 µM staurosporine and 50 µM LY294002 
for 2.5 h
Negative for AKT, ERK1/2, MEK1/2 phos-
phorylation
Indivumed GmbH
HT29 Human colon adenocarcinoma Untreated Positive for c-MET phosphorylation Indivumed GmbH
HT29 Human colon adenocarcinoma Calf intestinal alkaline phosphatase for 
50 min
Negative for c-MET phosphorylation Indivumed GmbH
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NanoPro1000 analysis
The NanoPro1000 system is a new proteomic technology 
that is used for the detailed characterization of cell sign-
aling processes in extremely small biological samples. It 
is an automated capillary-based immunoassay platform, 
which allows for the separation of proteins according to 
their isoelectric point (pI). Proteins and ampholytes are 
loaded into the capillary automatically and separated by 
charge and resolve according to their expected pI values. 
The separated proteins are then immobilized to the capil-
lary wall via a proprietary, photoactivated capture chemis-
try. Target proteins are identified using a primary antibody 
and immunoprobed using an HRP-conjugated secondary 
antibody and chemiluminescent substrate. The resulting 
chemiluminescent signal is detected and quantitated. Pro-
teins from complex biological samples are separated by iso-
electric focusing to resolve the various modification states 
of signaling proteins. Analysis of generated data was per-
formed using Compass software v1.8.2 (Cytel, Cambridge, 
MA, USA). Every NanoPro1000 run includes pI standard 
ladders in the applied separation gradient for signal cali-
bration. After the completion of a run, standards are set for 
controls and samples, enabling the determination of the pIs 
for detected signals. The Compass software then calculates 
the area under the curve (AUC) and the percentage of the 
area under the peak (% area) to predefined phosphorylated 
or unphosphorylated forms of the target. Control lysates 
and tissue lysates are measured in duplicate with a final 
protein concentration of 0.15  µg/µl (equal to 60  ng total 
protein in the capillary). The pan antibodies used (against 
AKT, ERK1/2, MEK1/2, and c-MET) detect total protein as 
well as phosphorylated isoforms (Table 2).
Meso scale discovery analysis
Tissue lysates of freshly frozen specimens from the 
patients analyzed in this study were prepared by cutting 
and homogenizing a 20 μm slice from each specimen. Pro-
tein concentration of the lysates was determined using a 
BCA assay (BCA kit; Sigma, Steinheim, Germany). EGFR 
protein was quantified using 96-well plates with cap-
ture antibodies based on the assay platform from Meso 
Scale Discovery (MSD; Gaithersburg, MD, USA) and the 
EGFR/pEGFR (Tyr1173) duplex assay kit. Assays were 
performed using 10  μg of tissue lysate according to the 
manufacturers’ instructions and analyzed with the SEC-
TOR Imager platform (MSD). Analyses were conducted 
in triplicate and arithmetic mean values were calculated. 
Mean values of post-surgery samples were compared with 
presurgery samples from the same patient. To account for 
inter-assay variation, lysates of stimulated human cells 
were used as positive and negative controls.
Statistical analysis
Protein phosphorylation data were analyzed using Com-
pass software v1.8.2. Data were statistically analyzed using 
GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, 
CA, USA). Descriptive column statistics of each data set 
were performed, including the Shapiro–Wilk test for nor-
mality. If the Shapiro–Wilk test revealed a non-Gaussian 
distribution (p ≤  0.05), data sets were tested for signifi-
cant differences using the Kruskal–Wallis test in combi-
nation with the Dunn post-test for multiple comparisons. 
If the Shapiro–Wilk test revealed a Gaussian distribution 
(p > 0.05), data sets were tested for significant differences 
using one-way analysis of variance in combination with 
the Dunnett post-test for multiple comparisons.
Results
Patient disposition and clinical data
In a previous part of the study a total of 50 patients with 
primary CRC who were scheduled for tumor resection 
surgery consented to study enrollment. A representa-
tive cohort of 20 patients was selected for this study, 
based on high tumor content and overall tissue quality. 
In total, 20 patients with primary CRC who were sched-
uled for tumor resection surgery consented to study 
enrollment. Additional file 1: Table S1 presents patient 
clinical data including tumor stage and grade. Surgi-
cal resection was conducted in two hospitals: the Alten 
Eichen Hospital, Hamburg, Germany, and the Israel-
itisches Krankenhaus, Hamburg, Germany. Proteomic 
analysis of AKT, ERK1/2, MEK1/2, EGFR and c-MET 
Table 2 NanoPro1000 assay conditions
Pan antibodies detecting the target signaling molecules were used under optimized assay conditions, as shown. HRP, horseradish peroxidase
HRP horseradish peroxidase
Target Primary antibody, dilution Secondary antibody Gradient Immobilization 
time (s)
AKT Anti-AKT (pan), 1:50 Anti-rabbit-HRP G2 pH 5‒8 (nested) 80
ERK1/2 Anti-ERK 1/2 (pan), ready to use Anti-rabbit-HRP G2 pH 5‒8 (nested) 80
MEK1/2 Anti-MEK1/2 (pan), 1:12.5 Anti-mouse-HRP G2 pH 5‒8 (nested) 80
c-MET Anti-c-MET (pan), 1:12.5 Anti-rabbit-HRP G2 pH 5‒8 (nested) 100
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phosphorylation was conducted for normal and tumor 
ischemic tissue samples from all 20 patients, and rela-
tive quantification of phosphorylation was calculated by 
determining the AUC of annotated peaks in relation to 
each other (% area).
Run controls and inter‑assay variation
To ensure the quality of the NanoPro1000 and Meso 
Scale Discovery assays, run controls were included in 
every measurement of patient samples. Run controls 
were then used to evaluate the inter-assay variation of 
measurements conducted on different days. The positive 
run controls (high phosphorylation) of the AKT, ERK1/2, 
MEK1/2, and c-MET assays were each used to calculate 
the coefficient of variation (CV) of assays for eight indi-
vidual runs per assay. The inter-assay variation for all 
assays was low, as shown in Fig. 2. In general, the assays 
showed a CV below 6  % (AKT, 4.1  %; ERK1/2, 3.5  %; 
MEK1/2, 4.2 %; and c-MET, 5.7 %).
Ischemia‑dependent regulation of AKT phosphorylation
The phosphorylation of AKT, overall and individual iso-
forms, was analyzed in relation to ischemia time. The 
representative AKT spectra and corresponding phos-
phorylation shown in Fig.  3a, b provide an impression 
of the generated data from cell-line run controls and 
patient samples. Therein, unphosphorylated isoforms of 
AKT are named “total 1–3” and phosphorylated states of 
these isoforms are named “phospho1-6.” The analysis of 
overall phosphorylation of AKT in response to ischemia 
revealed only minor fluctuations in normal and tumor 
tissue of all patients, as shown in Fig. 4a. In normal tis-
sues, a trend to increased phosphorylation in response to 
ischemia was detected, which reached statistical signifi-
cance when comparing N0 and N45.
In contrast to normal tissue, there was a trend towards 
decreased AKT phosphorylation in tumor tissue upon 
cold ischemia (Fig.  4a). Most patient samples (18/19) 
showed decreased AKT phosphorylation after 20  min 
of ischemia; however, this trend did not reach statisti-
cal significance (data not shown). Regarding the analysis 
of individual isoforms in relation to ischemia, Fig. 5a, b 
show representative spectra of changes in isoform phos-
phorylation between N0 and N45. The analysis of all 
individual isoforms of AKT in regard to ischemia time 
revealed statistically significant increased phosphoryla-
tion of two isoforms (phospho2 and phospho3), as well as 
downregulation of one unphosphorylated isoform (total 
1) between N0 and N45 in normal tissue (Fig. 5c). Rep-
resentative spectra for tumor tissue are shown in Fig. 5d, 
e. Phosphorylation of the isoform, phospho5, was sta-
tistically significantly decreased across all ischemia time 
points compared with T0, whereas phosphorylation of 
total 3 was significantly increased (Fig.  5f ). No statisti-
cally significant differences in overall AKT phosphoryla-
tion at baseline between normal and tumor tissue were 
observed.
Ischemia‑dependent regulation of ERK1/2 phosphorylation
Representative ERK1/2 phosphorylation spectra are 
shown in Fig. 3c, d. Therein, the identity of all peaks in 
the spectra of the NanoPro1000 ERK1/2 assay are fully 
elucidated, regarding the state of mono- or dual phos-
phorylation and assignment to ERK1 and ERK2, respec-
tively. Fluctuations in ERK1/2 phosphorylation detected 
in normal and tumor tissue samples of all patients in 
response to ischemia showed more than 0.8-fold changes 
in single patients (Fig. 4b). The overall phosphorylation of 
ERK1/2 in individual patients was also determined (data 
not shown), and an analysis of individual isoforms in rela-
tion to ischemia time was performed. The regulation of 
ERK1/2 phosphorylation was heterogeneous in the ana-
lyzed samples with a trend towards decreased phospho-
rylation in response to ischemia, although single patients 
showed increased phosphorylation of ERK1/2. In normal 
tissues, a trend towards decreased phosphorylation in 
response to ischemia was detected, but only reached sta-
tistical significance when comparing time points N0 and 
N10. The same trend towards decreased ERK1/2 phos-
phorylation upon cold ischemia was detected in tumor 
tissue and only showed statistical significance when 
comparing time points T0 and T10 (Fig. 4b). This trend 
towards decreased phosphorylation was not statistically 
significant at other time points.
Analysis of individual isoforms in regard to ischemia 
time revealed decreased phosphorylation of two 
In
te
r-
as
sa
y 
va
ria
tio
n
fo
ld
 c
ha
ng
e 
(r
un
1=
1)
0
0.5
1.0
1.5
AKT ERK1/2 MEK1/2 c-MET
Fig. 2 Inter-assay variation of NanoPro1000 assays AKT, ERK1/2, 
MEK1/2, and c-MET. Data were calculated from run controls of all runs 
(n = 8). Normalization for individual assays was performed to the first 
run performed and displayed as box-and-whisker plots. Boxes repre-
sent first and third quartile, whiskers represent minima and maxima, 
and solid lines within boxes indicate medians
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Page 7 of 15Unger et al. J Transl Med  (2016) 14:6 
double-phosphorylated isoforms (ppERK1 and ppERK2b) 
as well as an upregulation of unphosphorylated ERK2 
in normal tissue (Fig. 6c). Figure 6a, b show representa-
tive chemiluminescence spectra for change in ppERK1 
comparing time points N0 and N10. This change in the 
phosphorylated isoforms reached statistical significance 
when comparing N0 and N10. Increased unphosphoryl-
ated ERK2 was found to be statistically significant when 
comparing ischemia time points N10 and N20 with N0. 
In tumor tissue, unphosphorylated ERK1 was found to be 
statistically significant increased at T20 compared with 
T0 (Fig.  6f ). Representative chemiluminescence spec-
tra of change in ERK1 between T0 and T20 are shown 
in Fig. 6d, e. There were no other significant changes in 
ERK1/2 phosphorylation detected in tumor tissue.
At baseline (N and T  =  0), a difference in the mean 
phosphorylation of ERK1/2 was observed between nor-
mal tissue and tumor tissue. The mean baseline level of 
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Fig. 4 Changes in phosphorylation of AKT, ERK1/2, MEK1/2, and c-MET in response to ischemia. Time-dependent changes in phosphorylation of 
AKT (a), ERK1/2 (b), MEK1/2 (c), and c-MET (d) in normal (N) compared with tumor (T) tissue from 20 patients are shown by box-and-whisker plots. 
Boxes represent first and third quartile, whiskers represent minima and maxima, solid lines within boxes indicate medians. Results were displayed as 
fold changes normalized in normal tissue to sample NC4/N0 and in tumor tissue to sample NC4/T0. Kruskal–Wallis test and Dunn test for multiple 
comparisons or analysis of variance (ANOVA) were used for statistical analysis. N normal tissue, T tumor tissue, 0 before surgery, 10, 20, 45 10, 20, 
45 min after resection; ap ≤ 0.05; bp ≤ 0.01
(See figure on next page.) 
Fig. 5 Changes in isoform phosphorylation of the target signaling protein, AKT, in response to ischemia. Representative spectra of time-dependent 
changes in the phospho3 isoform phosphorylation of AKT between N0 and N45 in normal tissue are shown in a and b. An overview of all isoforms 
of AKT in normal tissue of all patients analyzed is shown in c; therein results were displayed as fold changes normalized in normal tissue to sample 
NC5/N0 and in tumor tissue to sample NC5/T0. The same graphs are shown for time-dependent changes between T0 and T20 in the phospho5 
isoform in tumor tissue (d, e). An overview of all isoforms of AKT in tumor tissue of all patients analyzed is shown in f. Kruskal–Wallis test and Dunn 
test for multiple comparisons or analysis of variance (ANOVA) were used for statistical analysis. N normal tissue, T tumor tissue, 0 before surgery, 10, 
20, 45 10, 20, 45 min after resection; Time points (10, 20, 45) are compared with time point 0; ap ≤ 0.05; bp ≤ 0.01; cp ≤ 0.001
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ERK1/2 phosphorylation was significantly (p  ≤  0.05) 
higher in normal tissue (Fig. 7a). The main driver of ele-
vated phosphorylation was the double phosphorylated 
form of ERK1, ppERK1 (Fig. 7b).
Ischemia‑dependent regulation of MEK1/2 
phosphorylation
The phosphorylation of MEK1/2, overall and individ-
ual isoforms, was analyzed in relation to ischemia time. 
Representative spectra of MEK1/2 and corresponding 
phosphorylation patterns are shown in Fig. 3e, f. Unphos-
phorylated isoforms of MEK1/2 are named “MEK1 and 
MEK2,” and phosphorylated states of these isoforms are 
named “phospho1-6”.
Changes in MEK1/2 phosphorylation following 
ischemia were minimal, with only marginally increased 
phosphorylation of MEK1/2. In tumor tissue, a trend 
towards decreased MEK1/2 phosphorylation was 
detected, and showed statistical significance when com-
paring time points T0 and T10 (Fig. 4c). This decreased 
phosphorylation was not statistically significant at other 
time points. Although there was no statistically signifi-
cant change in overall phosphorylation of MEK1/2 in 
normal tissue, some statistically significant changes in the 
phosphorylation of individual isoforms of MEK1/2 were 
observed (Fig.  8a). In normal tissue, phosphorylation of 
the phospho4 isoform decreased in response to ischemia; 
this reached statistical significance at time points N20 
and N45, compared with N0. In contrast, increased phos-
phorylation of the phospho5 isoform was detected, with 
statistical significance reached at N45, compared with 
N0. The unphosphorylated isoform, MEK2, decreased in 
response to ischemia, reaching statistical significance at 
N20 and N45, compared with N0.
In tumor tissue, the phospho6 isoform decreased signif-
icantly in response to a short period of ischemia of 10 min 
(T10); this reached statistical significance at T10 and T20, 
compared with T0 (Fig.  8b). In contrast to normal tis-
sue, decreases in the phospho5 isoforms were statistically 
significant at all time points (T10, T20, T45), compared 
with T0. These significant decreases of the phospho5 and 
phospho6 isoforms contributed to the significant decrease 
of the overall phosphorylation of MEK1/2 in tumor tissue 
at the time point T10, compared with T0.
At baseline, no differences were observed in the relative 
phosphorylation of MEK1/2 in normal tissue compared 
a b
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Fig. 6 Changes in isoform phosphorylation of the target signaling protein, ERK1/2, in response to ischemia. Representative spectra of time-
dependent changes in the ppERK1 isoform phosphorylation of ERK1/2 between N0 and N10 in normal tissue are shown in a and b. An overview 
of all isoforms of ERK1/2 in normal tissue of all patients analyzed is shown in c; therein results were displayed as fold changes normalized in normal 
tissue to sample NC5/N0 and in tumor tissue to sample NC5/T0. The same graphs are shown for time-dependent changes in the ERK1 isoform 
between T0 and T20 in tumor tissue (d, e). An overview of all isoforms of ERK1/2 in tumor tissue of all patients analyzed is shown in f. Kruskal–Wal-
lis test and Dunn test for multiple comparisons or analysis of variance (ANOVA) were used for statistical analysis. N normal tissue, T tumor tissue, 0 
before surgery, 10, 20, 45 10, 20, 45 min after resection; Time points (10, 20, 45) are compared with time point 0; ap ≤ 0.01; bp ≤ 0.05
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with tumor tissue. Fluctuations in MEK1/2 phosphoryla-
tion due to ischemia time was more heterogeneous in 
tumor tissue compared to normal tissue, i.e. baseline lev-
els varied more between individual patient samples.
Ischemia‑dependent regulation of c‑MET phosphorylation
The phosphorylation of c-MET, overall and individual 
isoforms, was analyzed in relation to ischemia time. 
Representative spectra of c-MET and corresponding 
phosphorylation are shown in Fig. 3g, h. Unphosphoryl-
ated isoforms of c-MET are named “total 1” and “total 2,” 
and phosphorylated states of these isoforms are named 
“phospho1-4.”
The results of the NanoPro1000 analysis showed 
increased fluctuations in c-MET phosphorylation in 
normal compared with tumor tissue in response to 
ischemia (Fig.  4d). In normal tissues, a trend towards 
decreased phosphorylation of c-MET in response to 
ischemia was detected, reaching statistical signifi-
cance after 20  min (N20) of ischemia. In tumor tis-
sue, no statistically significant trend towards changes 
in c-MET phosphorylation upon cold ischemia was 
detected (Fig. 4d). In normal tissue, significant change 
in the overall phosphorylation of c-MET was detected 
following 20  min (N20) of ischemia, which was also 
present in the analysis of individual isoforms (Fig. 9a). 
In normal tissue, the phospho2 isoform decreased in 
response to ischemia; this reached statistical signifi-
cance at N20, compared with N0. These significant 
decreases in the phospho2 isoforms contributed to 
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the significant decrease in overall phosphorylation of 
c-MET in normal tissue at N20, compared with N0. 
There were no significant changes in the phosphoryla-
tion of the c-MET isoform in tumor tissue (Fig.  9b). 
At baseline, increased phosphorylation of c-MET was 
observed in normal tissue compared with tumor tissue 
(Fig. 4d).
Ischemia‑dependent regulation of EGFR phosphorylation
The expression and phosphorylation of EGFR was meas-
ured using the MSD technology. There were no signifi-
cant changes in expression and/or phosphorylation of the 
receptor in relation to ischemia time (Additional file  2: 
Figure S1), for both normal and tumor tissue samples 
from the 20 patients analyzed in this study.
Discussion
The identification of biomarkers for the stratification 
of cancer patients by stage of disease, prognosis, and 
administration of the most appropriate targeted anti-
cancer treatment depends upon the availability and col-
lection of human biospecimens. Biospecimens used for 
patient stratification in the clinical setting have to reflect 
the molecular reality in cancer patients and not be biased 
by factors such as ischemia. Anticancer treatments tar-
geting specific molecular markers are widely used for the 
clinical management of patients with CRC. One of these 
molecular targets is the EGFR and its downstream sign-
aling molecules within the AKT and MAPK pathways 
[19]. In addition to the mutation status of EGFR itself, 
and downstream signaling molecules like KRAS, the 
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proteomic analysis of kinase activation becomes more 
and more clinically relevant. Compared with the linear 
output of mutation analysis, the multidimensional infor-
mation obtained by proteomic pathways analysis may be 
useful when analyzing reasons for therapeutic resistance 
and sample heterogeneity, even in patient cohorts with 
similar genotype [20–22].
In the current study, normal and tumor tissue from 20 
selected patients with CRC were analyzed for ischemia-
induced changes in protein phosphorylation and for 
changes in the phosphorylation of isoforms of selected 
proteins. The analyzed proteins, ERK1/2, AKT, MEK1/2, 
EGFR and c-MET are potentially clinically relevant 
molecular markers for the characterization of tumors 
according to prognosis [23–25] and anticancer therapy 
[26, 27]. The analysis was conducted using the relatively 
novel antibody-based NanoPro1000 technology. This 
technology enables the detection of overall phospho-
rylation of proteins as well as the phosphorylation of 
individual isoforms. Since isoforms of signaling proteins 
have distinct biological functions [28–30], it is even more 
important to analyze ischemia-induced changes and 
thus identify markers or signatures indicating alteration 
of molecular targets. In order to detect tumor-specific 
signals, the tumor content of samples used in this study 
was adjusted to ≥50 % by macrodissection or microdis-
section, which avoids strong dilution of tumor-specific 
signals by normal cells and tissues present in the sample. 
This was shown to be particularly important in this study 
given that the baseline level of ERK1/2 phosphorylation 
was higher in normal tissue compared with tumor tissue. 
In this study, inter-assay variation, as measured using run 
controls, was below 10 percent. This indicates that the 
assays were robust and reproducible in the time frame of 
the study and that small changes in protein phosphoryla-
tion were detectable, even when comparing runs on dif-
ferent days.
In this study, ischemia-induced changes in overall 
phosphorylation of the signaling proteins analyzed were 
not as large as expected. However, we were able to iden-
tify significant changes in isoform phosphorylation that 
can be potentially assigned to specific phosphosites and 
later be interpreted in a biological context. Further-
more, we showed different degrees of baseline protein 
phosphorylation when comparing normal and tumor 
tissue, indicating the importance of analyzing tumor 
content of tissue samples. Specifically, the phosphoryla-
tion of c-MET, a heterodimeric transmembrane recep-
tor [31], has in this study been found to be significantly 
decreased after 20  min of ischemia in normal tissue, 
whereas no change has been detected in tumor tissues. 
The differences in phosphorylation between tumor tis-
sue and normal tissue might be explained by a higher 
and more heterogeneous baseline level of phospho-
rylation of c-MET in tumor tissue. This heterogeneity 
might reflect patients` individuality as well as molecu-
lar changes due to cancer, which may disguise any sig-
nificant change due to ischemia in the whole cohort 
of tumor patients. The analysis of isoforms of c-Met 
revealed statistically significant changes in phospho2 
following 20  min of ischemia in normal tissues (see 
Fig.  9), which is in accordance with the regulation of 
the overall phosphorylation level. It is unclear whether 
patients with high baseline levels of c-MET phosphoryl-
ation respond to ischemia differently than patients with 
no c-MET phosphorylation at baseline. In addition, 
the presence of high levels of c-MET protein and RNA 
expression does not correlate with MET gene amplifica-
tion or pathway activation [32].
The EGFR (ErbB-1) is a member of the ErbB family 
of receptors, and a clinically targeted receptor tyrosine 
kinase. Although the expression and phosphorylation 
of this receptor has not been found to be influenced by 
ischemia, downstream signaling of the receptor via the 
Akt and/or MAPK pathways was influenced by ischemia. 
For example AKT, the key signaling protein of the AKT 
pathway, displayed significantly increased levels of phos-
pho2 and phospho3 isoform phosphorylation in normal 
tissue and decreased levels of phospho5 phosphoryla-
tion in tumor tissue. Levels of individual AKT isoforms 
have been shown to correlate with patient prognosis 
and response to anticancer therapy [33, 34]. Changes in 
isoforms may be the main driver of changes in overall 
phosphorylation. In this study, changes in isoform phos-
phorylation reached significance at some time points, 
whereas changes in overall phosphorylation did not. 
Since AKT inhibits apoptosis and regulates cell growth, 
survival, and proliferation, and facilitates recovery from 
ischemia, one could have expected increased levels of 
AKT phosphorylation in response to ischemia, as seen in 
normal tissues.
Crosstalk exists between the PI3K-AKT pathway and 
the MAP-kinase pathway. These are signal transduction 
pathways that involve a chain of dual-specificity kinases 
activating each other in series. MAP-kinase pathway 
dysregulation is common during oncogenesis, as well as 
in other diseases [35]. In this study, MEK1/2 phospho-
rylation was found to be downregulated in tumor tissue 
only after 10 min of ischemia, whereas no statistically sig-
nificant change in phosphorylation was detected in nor-
mal tissue. Although there was no significant change in 
the overall phosphorylation of MEK1/2 in normal tissue 
in response to ischemia, the analysis of phosphorylation 
levels of individual isoforms revealed a statistically signifi-
cant decrease in the MEK1/2 isoform phospho4 and an 
increase in phospho5. This inverse relationship between 
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the two isoforms could be explained by the assumption 
that the regulated phosphosites could either be inhibit-
ing or activating protein activity. In tumor tissue, two 
MEK1/2 isoforms have been found to be significantly 
downregulated, namely phospho5 and phospho6. In gen-
eral, the heterogeneity of MEK1/2 phosphorylation levels 
in tumor as well as normal tissue at baseline was low com-
pared with the other signaling proteins analyzed, indicat-
ing a low heterogeneity between individual patients.
Results also revealed decreased phosphorylation of 
ERK1/2 in response to ischemia in normal as well as 
tumor tissue after 10 min of ischemia, similar to MEK1/2 
in tumor tissue. The decreased phosphorylation in nor-
mal tissue after 10  min of ischemia was greater than in 
tumor tissue and accompanied by statistically significant 
changes in the phosphorylation of the ppERK2b and 
ppERK1 isoforms (see Fig. 7a, b).
In addition, the detected differences in baseline phos-
phorylation levels of ERK1/2 when comparing normal 
and tumor tissue is in contrast to the often assumed 
hyperactivation of the MAP-kinase pathway in cancer. 
Consequently, this is of particular importance for the 
analysis of clinical biospecimens, since they comprise 
a mixture of normal and tumor cell populations as well 
as stromal tissue and immune cells. Thus, contamina-
tion of tumor-specific ERK1/2 will occur when analyzing 
biospecimens with unknown tumor content, potentially 
leading to false results, with consequences for the clinical 
management of disease.
Conclusion
The data generated in this study differ compared with 
data described in a previous study using other technol-
ogies [9]. In general, the comparison of protein phos-
phorylation data from different studies, using different 
technologies, is hindered by the specificity of antibod-
ies and the molecular technique used. For example, the 
immobilization of proteins within different molecular 
techniques (e.g., immunohistochemistry, western blot, 
ELISA) varies considerably. Different protein modifica-
tions in turn may influence the binding of the antibody 
to its target protein. The possibility to check the antibody 
for specificity prior to conducting experiments is criti-
cal in order to generate valid results. Furthermore, the 
NanoPro1000 technology uses pan antibodies directed 
against target proteins to detect unphosphorylated and 
phosphorylated forms of the protein simultaneously, 
circumventing the use of different antibodies (total and 
phospho-specific antibodies). In future studies, the regu-
lation of individual isoforms of signaling proteins has to 
be elucidated in terms of the identity of regulated phos-
phosites (e.g. Ser473 for Akt), in order to be able to assess 
the biological impact of the regulation (i.e., activating 
or inhibiting kinase activity) and impact on anticancer 
therapy. This will give further insights into the effects of 
ischemia on tissues, and will determine the types of phos-
phorylation of signaling molecules that are activated by 
cells themselves, and the types that occur when cells die 
due to ischemia. This will be achieved by further experi-
ments using isoform- and phospho-specific antibodies, 
as well as phosphatase treatments.
In conclusion, this study provides new insights into 
the biology of ischemia-induced changes in normal and 
tumor tissue. This may have clinical relevance in terms 
of identifying markers of tissue quality, stratification of 
patients and other relevant parameters.
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